
    
      STUDY OBJECTIVES

      Primary:

      â€¢ To determine tumor GR, AR, JAK and other Hsp90 client protein expression before and after
      two weeks of ganetespib monotherapy

      Secondary:

        -  To determine the pathological Complete Response (pCR) rate associated with weekly
           treatment of ganetespib plus paclitaxel followed by the combination treatment of
           doxorubicin plus cyclophosphamide

        -  To characterize the toxicity of study treatment
    
  